Global Peptide Therapeutics Market
Global Peptide Therapeutics Market

Peptide Therapeutics Comprehensive Study by Type (Generic, Innovative), Application (Cancer Treatment, Metabolic, Cardiovascular Disorder, Respiratory, GIT, Anti-infection, Pain, Dermatology, CNS, Renal, Others), Administration Outlook (Parenteral Route, Oral Route, Pulmonary, Mucosal, Others), Manufacturers (In-house, Outsourced), Type of Molecule (Vasopressin, Somatostatin, Calcitonin, Natriuretic, Immunopeptide), Synthesis Technology Outlook (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology) Players and Region - Global Market Outlook to 2024

Peptide Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026 | CAGR: 8.3%  

Apr 2019 Edition 237 Pages 222 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Market Snapshot:
Peptide Therapeutics refer to chemical modification of protein drug and peptide to improve enzymatic strength of the drugs. There has been rapid growth in demand of peptide therapeutics owing to the increasing prevalence of cancer, cardiovascular diseases, Diabetics Mellitus and other life-threatening diseases. For instance, In the United States alone around 1,735,350 new cases of cancer have been recorded in 2018. Rising government initiatives and technological development such as the evolution of hybrid technology which provides easy use of both liquid and solid phase peptide with reduced production time expected to drive the peptide therapeutics market in the long-standing.

Market Trend
Emphasizing on Low Waste Generation during Production of Peptide Therapeutics

Market Drivers
Growing Application of Hybrid Technology in Peptide Therapeutics and Increasing Number of Cancer and Diabetics Mellitus Patients

Opportunities
Development of Automation Techniques Associated with Peptide Therapeutics

The Players Covered in the Study are:
Eli Lilly and Company (United States), Pfizer, Inc. (United States), Amgen, Inc. (United States), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceuticals Industries Ltd. (Israel), Lonza Inc. (United States), Protagonist Therapeutics, Inc. (United States), Bristol-Myers Squibb (United States), AstraZeneca PLC (United Kingdom), GlaxoSmithKline plc (United Kingdom), Incyte Corporation (United States), AstraZeneca (United Kingdom), Nektar Therapeutics (United States), Next Cure, Inc. (United States) and Dicerna Pharmaceuticals, Inc. (United States)

Available Customization:
List of players that can be included in the study on immediate basis are Sanofi (France), Daiichi Sankyo Co. (Japan), Novartis AG (Switzerland) and Novo Nordisk A/S (Denmark).

Report Objectives / Segmentation Covered
By Type
  • Generic
  • Innovative
By Application
  • Cancer Treatment
  • Metabolic
  • Cardiovascular Disorder
  • Respiratory
  • GIT
  • Anti-infection
  • Pain
  • Dermatology
  • CNS
  • Renal
  • Others
By Administration Outlook
  • Parenteral Route
  • Oral Route
  • Pulmonary
  • Mucosal
  • Others

By Manufacturers
  • In-house
  • Outsourced

By Type of Molecule
  • Vasopressin
  • Somatostatin
  • Calcitonin
  • Natriuretic
  • Immunopeptide

By Synthesis Technology Outlook
  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Application of Hybrid Technology in Peptide Therapeutics
      • 3.2.2. Increasing Number of Cancer and Diabetics Mellitus Patients
    • 3.3. Market Challenges
      • 3.3.1. Production of Cost-effective Peptide Therapeutics
      • 3.3.2. Low Shelf-Life of Peptide Therapeutics
    • 3.4. Market Trends
      • 3.4.1. Emphasizing on Low Waste Generation during Production of Peptide Therapeutics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Peptide Therapeutics, by Type, Application, Administration Outlook , Manufacturers , Type of Molecule, Synthesis Technology Outlook and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Peptide Therapeutics (Value)
      • 5.2.1. Global Peptide Therapeutics by: Type (Value)
        • 5.2.1.1. Generic
        • 5.2.1.2. Innovative
      • 5.2.2. Global Peptide Therapeutics by: Application (Value)
        • 5.2.2.1. Cancer Treatment
        • 5.2.2.2. Metabolic
        • 5.2.2.3. Cardiovascular Disorder
        • 5.2.2.4. Respiratory
        • 5.2.2.5. GIT
        • 5.2.2.6. Anti-infection
        • 5.2.2.7. Pain
        • 5.2.2.8. Dermatology
        • 5.2.2.9. CNS
        • 5.2.2.10. Renal
        • 5.2.2.11. Others
      • 5.2.3. Global Peptide Therapeutics by: Type of Molecule (Value)
        • 5.2.3.1. Vasopressin
        • 5.2.3.2. Somatostatin
        • 5.2.3.3. Calcitonin
        • 5.2.3.4. Natriuretic
        • 5.2.3.5. Immunopeptide
      • 5.2.4. Global Peptide Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Peptide Therapeutics (Price)
      • 5.3.1. Global Peptide Therapeutics by: Type (Price)
  • 6. Peptide Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceuticals Industries Ltd. (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lonza Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Protagonist Therapeutics, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol-Myers Squibb (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca PLC (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Incyte Corporation (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. AstraZeneca (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Nektar Therapeutics (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Next Cure, Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Dicerna Pharmaceuticals, Inc. (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Peptide Therapeutics Sale, by Type, Application, Administration Outlook , Manufacturers , Type of Molecule, Synthesis Technology Outlook and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Peptide Therapeutics (Value)
      • 7.2.1. Global Peptide Therapeutics by: Type (Value)
        • 7.2.1.1. Generic
        • 7.2.1.2. Innovative
      • 7.2.2. Global Peptide Therapeutics by: Application (Value)
        • 7.2.2.1. Cancer Treatment
        • 7.2.2.2. Metabolic
        • 7.2.2.3. Cardiovascular Disorder
        • 7.2.2.4. Respiratory
        • 7.2.2.5. GIT
        • 7.2.2.6. Anti-infection
        • 7.2.2.7. Pain
        • 7.2.2.8. Dermatology
        • 7.2.2.9. CNS
        • 7.2.2.10. Renal
        • 7.2.2.11. Others
      • 7.2.3. Global Peptide Therapeutics by: Type of Molecule (Value)
        • 7.2.3.1. Vasopressin
        • 7.2.3.2. Somatostatin
        • 7.2.3.3. Calcitonin
        • 7.2.3.4. Natriuretic
        • 7.2.3.5. Immunopeptide
      • 7.2.4. Global Peptide Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Peptide Therapeutics (Price)
      • 7.3.1. Global Peptide Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Peptide Therapeutics: by Type(USD Million)
  • Table 2. Peptide Therapeutics Generic , by Region USD Million (2013-2018)
  • Table 3. Peptide Therapeutics Innovative , by Region USD Million (2013-2018)
  • Table 4. Peptide Therapeutics: by Application(USD Million)
  • Table 5. Peptide Therapeutics Cancer Treatment , by Region USD Million (2013-2018)
  • Table 6. Peptide Therapeutics Metabolic , by Region USD Million (2013-2018)
  • Table 7. Peptide Therapeutics Cardiovascular Disorder , by Region USD Million (2013-2018)
  • Table 8. Peptide Therapeutics Respiratory , by Region USD Million (2013-2018)
  • Table 9. Peptide Therapeutics GIT , by Region USD Million (2013-2018)
  • Table 10. Peptide Therapeutics Anti-infection , by Region USD Million (2013-2018)
  • Table 11. Peptide Therapeutics Pain , by Region USD Million (2013-2018)
  • Table 12. Peptide Therapeutics Dermatology , by Region USD Million (2013-2018)
  • Table 13. Peptide Therapeutics CNS , by Region USD Million (2013-2018)
  • Table 14. Peptide Therapeutics Renal , by Region USD Million (2013-2018)
  • Table 15. Peptide Therapeutics Others , by Region USD Million (2013-2018)
  • Table 16. Peptide Therapeutics: by Type of Molecule(USD Million)
  • Table 17. Peptide Therapeutics Vasopressin , by Region USD Million (2013-2018)
  • Table 18. Peptide Therapeutics Somatostatin , by Region USD Million (2013-2018)
  • Table 19. Peptide Therapeutics Calcitonin , by Region USD Million (2013-2018)
  • Table 20. Peptide Therapeutics Natriuretic , by Region USD Million (2013-2018)
  • Table 21. Peptide Therapeutics Immunopeptide , by Region USD Million (2013-2018)
  • Table 22. South America Peptide Therapeutics, by Country USD Million (2013-2018)
  • Table 23. South America Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 24. South America Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 25. South America Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 26. South America Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 27. South America Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 28. South America Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 29. Brazil Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 30. Brazil Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 31. Brazil Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 32. Brazil Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 33. Brazil Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 34. Brazil Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 35. Argentina Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 36. Argentina Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 37. Argentina Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 38. Argentina Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 39. Argentina Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 40. Argentina Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 41. Rest of South America Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 42. Rest of South America Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 43. Rest of South America Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 44. Rest of South America Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 45. Rest of South America Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 46. Rest of South America Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 47. Asia Pacific Peptide Therapeutics, by Country USD Million (2013-2018)
  • Table 48. Asia Pacific Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 49. Asia Pacific Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 50. Asia Pacific Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 51. Asia Pacific Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 52. Asia Pacific Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 53. Asia Pacific Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 54. China Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 55. China Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 56. China Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 57. China Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 58. China Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 59. China Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 60. Japan Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 61. Japan Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 62. Japan Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 63. Japan Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 64. Japan Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 65. Japan Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 66. India Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 67. India Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 68. India Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 69. India Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 70. India Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 71. India Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 72. South Korea Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 73. South Korea Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 74. South Korea Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 75. South Korea Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 76. South Korea Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 77. South Korea Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 78. Taiwan Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 79. Taiwan Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 80. Taiwan Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 81. Taiwan Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 82. Taiwan Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 83. Taiwan Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 84. Australia Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 85. Australia Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 86. Australia Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 87. Australia Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 88. Australia Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 89. Australia Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 90. Rest of Asia-Pacific Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 91. Rest of Asia-Pacific Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 92. Rest of Asia-Pacific Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 93. Rest of Asia-Pacific Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 94. Rest of Asia-Pacific Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 95. Rest of Asia-Pacific Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 96. Europe Peptide Therapeutics, by Country USD Million (2013-2018)
  • Table 97. Europe Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 98. Europe Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 99. Europe Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 100. Europe Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 101. Europe Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 102. Europe Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 103. Germany Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 104. Germany Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 105. Germany Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 106. Germany Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 107. Germany Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 108. Germany Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 109. France Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 110. France Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 111. France Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 112. France Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 113. France Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 114. France Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 115. Italy Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 116. Italy Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 117. Italy Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 118. Italy Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 119. Italy Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 120. Italy Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 121. United Kingdom Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 122. United Kingdom Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 123. United Kingdom Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 124. United Kingdom Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 125. United Kingdom Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 126. United Kingdom Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 127. Netherlands Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 128. Netherlands Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 129. Netherlands Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 130. Netherlands Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 131. Netherlands Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 132. Netherlands Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 133. Rest of Europe Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 134. Rest of Europe Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 135. Rest of Europe Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 136. Rest of Europe Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 137. Rest of Europe Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 138. Rest of Europe Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 139. MEA Peptide Therapeutics, by Country USD Million (2013-2018)
  • Table 140. MEA Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 141. MEA Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 142. MEA Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 143. MEA Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 144. MEA Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 145. MEA Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 146. Middle East Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 147. Middle East Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 148. Middle East Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 149. Middle East Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 150. Middle East Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 151. Middle East Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 152. Africa Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 153. Africa Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 154. Africa Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 155. Africa Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 156. Africa Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 157. Africa Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 158. North America Peptide Therapeutics, by Country USD Million (2013-2018)
  • Table 159. North America Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 160. North America Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 161. North America Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 162. North America Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 163. North America Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 164. North America Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 165. United States Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 166. United States Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 167. United States Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 168. United States Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 169. United States Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 170. United States Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 171. Canada Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 172. Canada Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 173. Canada Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 174. Canada Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 175. Canada Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 176. Canada Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 177. Mexico Peptide Therapeutics, by Type USD Million (2013-2018)
  • Table 178. Mexico Peptide Therapeutics, by Application USD Million (2013-2018)
  • Table 179. Mexico Peptide Therapeutics, by Administration Outlook USD Million (2013-2018)
  • Table 180. Mexico Peptide Therapeutics, by Manufacturers USD Million (2013-2018)
  • Table 181. Mexico Peptide Therapeutics, by Type of Molecule USD Million (2013-2018)
  • Table 182. Mexico Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2013-2018)
  • Table 183. Peptide Therapeutics: by Type(USD/Units)
  • Table 184. Company Basic Information, Sales Area and Its Competitors
  • Table 185. Company Basic Information, Sales Area and Its Competitors
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Peptide Therapeutics: by Type(USD Million)
  • Table 200. Peptide Therapeutics Generic , by Region USD Million (2019-2024)
  • Table 201. Peptide Therapeutics Innovative , by Region USD Million (2019-2024)
  • Table 202. Peptide Therapeutics: by Application(USD Million)
  • Table 203. Peptide Therapeutics Cancer Treatment , by Region USD Million (2019-2024)
  • Table 204. Peptide Therapeutics Metabolic , by Region USD Million (2019-2024)
  • Table 205. Peptide Therapeutics Cardiovascular Disorder , by Region USD Million (2019-2024)
  • Table 206. Peptide Therapeutics Respiratory , by Region USD Million (2019-2024)
  • Table 207. Peptide Therapeutics GIT , by Region USD Million (2019-2024)
  • Table 208. Peptide Therapeutics Anti-infection , by Region USD Million (2019-2024)
  • Table 209. Peptide Therapeutics Pain , by Region USD Million (2019-2024)
  • Table 210. Peptide Therapeutics Dermatology , by Region USD Million (2019-2024)
  • Table 211. Peptide Therapeutics CNS , by Region USD Million (2019-2024)
  • Table 212. Peptide Therapeutics Renal , by Region USD Million (2019-2024)
  • Table 213. Peptide Therapeutics Others , by Region USD Million (2019-2024)
  • Table 214. Peptide Therapeutics: by Type of Molecule(USD Million)
  • Table 215. Peptide Therapeutics Vasopressin , by Region USD Million (2019-2024)
  • Table 216. Peptide Therapeutics Somatostatin , by Region USD Million (2019-2024)
  • Table 217. Peptide Therapeutics Calcitonin , by Region USD Million (2019-2024)
  • Table 218. Peptide Therapeutics Natriuretic , by Region USD Million (2019-2024)
  • Table 219. Peptide Therapeutics Immunopeptide , by Region USD Million (2019-2024)
  • Table 220. South America Peptide Therapeutics, by Country USD Million (2019-2024)
  • Table 221. South America Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 222. South America Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 223. South America Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 224. South America Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 225. South America Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 226. South America Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 227. Brazil Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 228. Brazil Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 229. Brazil Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 230. Brazil Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 231. Brazil Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 232. Brazil Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 233. Argentina Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 234. Argentina Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 235. Argentina Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 236. Argentina Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 237. Argentina Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 238. Argentina Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 239. Rest of South America Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 240. Rest of South America Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 241. Rest of South America Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 242. Rest of South America Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 243. Rest of South America Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 244. Rest of South America Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 245. Asia Pacific Peptide Therapeutics, by Country USD Million (2019-2024)
  • Table 246. Asia Pacific Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 247. Asia Pacific Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 248. Asia Pacific Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 249. Asia Pacific Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 250. Asia Pacific Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 251. Asia Pacific Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 252. China Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 253. China Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 254. China Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 255. China Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 256. China Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 257. China Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 258. Japan Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 259. Japan Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 260. Japan Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 261. Japan Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 262. Japan Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 263. Japan Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 264. India Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 265. India Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 266. India Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 267. India Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 268. India Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 269. India Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 270. South Korea Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 271. South Korea Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 272. South Korea Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 273. South Korea Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 274. South Korea Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 275. South Korea Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 276. Taiwan Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 277. Taiwan Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 278. Taiwan Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 279. Taiwan Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 280. Taiwan Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 281. Taiwan Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 282. Australia Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 283. Australia Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 284. Australia Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 285. Australia Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 286. Australia Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 287. Australia Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 288. Rest of Asia-Pacific Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 289. Rest of Asia-Pacific Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 290. Rest of Asia-Pacific Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 291. Rest of Asia-Pacific Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 292. Rest of Asia-Pacific Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 293. Rest of Asia-Pacific Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 294. Europe Peptide Therapeutics, by Country USD Million (2019-2024)
  • Table 295. Europe Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 296. Europe Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 297. Europe Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 298. Europe Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 299. Europe Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 300. Europe Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 301. Germany Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 302. Germany Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 303. Germany Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 304. Germany Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 305. Germany Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 306. Germany Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 307. France Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 308. France Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 309. France Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 310. France Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 311. France Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 312. France Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 313. Italy Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 314. Italy Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 315. Italy Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 316. Italy Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 317. Italy Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 318. Italy Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 319. United Kingdom Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 320. United Kingdom Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 321. United Kingdom Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 322. United Kingdom Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 323. United Kingdom Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 324. United Kingdom Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 325. Netherlands Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 326. Netherlands Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 327. Netherlands Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 328. Netherlands Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 329. Netherlands Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 330. Netherlands Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 331. Rest of Europe Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 332. Rest of Europe Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 333. Rest of Europe Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 334. Rest of Europe Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 335. Rest of Europe Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 336. Rest of Europe Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 337. MEA Peptide Therapeutics, by Country USD Million (2019-2024)
  • Table 338. MEA Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 339. MEA Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 340. MEA Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 341. MEA Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 342. MEA Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 343. MEA Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 344. Middle East Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 345. Middle East Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 346. Middle East Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 347. Middle East Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 348. Middle East Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 349. Middle East Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 350. Africa Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 351. Africa Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 352. Africa Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 353. Africa Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 354. Africa Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 355. Africa Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 356. North America Peptide Therapeutics, by Country USD Million (2019-2024)
  • Table 357. North America Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 358. North America Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 359. North America Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 360. North America Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 361. North America Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 362. North America Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 363. United States Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 364. United States Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 365. United States Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 366. United States Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 367. United States Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 368. United States Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 369. Canada Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 370. Canada Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 371. Canada Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 372. Canada Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 373. Canada Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 374. Canada Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 375. Mexico Peptide Therapeutics, by Type USD Million (2019-2024)
  • Table 376. Mexico Peptide Therapeutics, by Application USD Million (2019-2024)
  • Table 377. Mexico Peptide Therapeutics, by Administration Outlook USD Million (2019-2024)
  • Table 378. Mexico Peptide Therapeutics, by Manufacturers USD Million (2019-2024)
  • Table 379. Mexico Peptide Therapeutics, by Type of Molecule USD Million (2019-2024)
  • Table 380. Mexico Peptide Therapeutics, by Synthesis Technology Outlook USD Million (2019-2024)
  • Table 381. Peptide Therapeutics: by Type(USD/Units)
  • Table 382. Research Programs/Design for This Report
  • Table 383. Key Data Information from Secondary Sources
  • Table 384. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Peptide Therapeutics: by Type USD Million (2013-2018)
  • Figure 5. Global Peptide Therapeutics: by Application USD Million (2013-2018)
  • Figure 6. Global Peptide Therapeutics: by Type of Molecule USD Million (2013-2018)
  • Figure 7. South America Peptide Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Peptide Therapeutics Share (%), by Country
  • Figure 9. Europe Peptide Therapeutics Share (%), by Country
  • Figure 10. MEA Peptide Therapeutics Share (%), by Country
  • Figure 11. North America Peptide Therapeutics Share (%), by Country
  • Figure 12. Global Peptide Therapeutics: by Type USD/Units (2013-2018)
  • Figure 13. Global Peptide Therapeutics share by Players 2018 (%)
  • Figure 14. Global Peptide Therapeutics share by Players (Top 3) 2018(%)
  • Figure 15. Global Peptide Therapeutics share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 18. Eli Lilly and Company (United States) Revenue: by Geography 2018
  • Figure 19. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer, Inc. (United States) Revenue: by Geography 2018
  • Figure 21. Amgen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Amgen, Inc. (United States) Revenue: by Geography 2018
  • Figure 23. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2018
  • Figure 25. Teva Pharmaceuticals Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 26. Teva Pharmaceuticals Industries Ltd. (Israel) Revenue: by Geography 2018
  • Figure 27. Lonza Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Lonza Inc. (United States) Revenue: by Geography 2018
  • Figure 29. Protagonist Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Protagonist Therapeutics, Inc. (United States) Revenue: by Geography 2018
  • Figure 31. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bristol-Myers Squibb (United States) Revenue: by Geography 2018
  • Figure 33. AstraZeneca PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. AstraZeneca PLC (United Kingdom) Revenue: by Geography 2018
  • Figure 35. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2018
  • Figure 37. Incyte Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 38. Incyte Corporation (United States) Revenue: by Geography 2018
  • Figure 39. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. AstraZeneca (United Kingdom) Revenue: by Geography 2018
  • Figure 41. Nektar Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 42. Nektar Therapeutics (United States) Revenue: by Geography 2018
  • Figure 43. Next Cure, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Next Cure, Inc. (United States) Revenue: by Geography 2018
  • Figure 45. Dicerna Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Dicerna Pharmaceuticals, Inc. (United States) Revenue: by Geography 2018
  • Figure 47. Global Peptide Therapeutics: by Type USD Million (2019-2024)
  • Figure 48. Global Peptide Therapeutics: by Application USD Million (2019-2024)
  • Figure 49. Global Peptide Therapeutics: by Type of Molecule USD Million (2019-2024)
  • Figure 50. South America Peptide Therapeutics Share (%), by Country
  • Figure 51. Asia Pacific Peptide Therapeutics Share (%), by Country
  • Figure 52. Europe Peptide Therapeutics Share (%), by Country
  • Figure 53. MEA Peptide Therapeutics Share (%), by Country
  • Figure 54. North America Peptide Therapeutics Share (%), by Country
  • Figure 55. Global Peptide Therapeutics: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Eli Lilly and Company (United States)
  • Pfizer, Inc. (United States)
  • Amgen, Inc. (United States)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • Lonza Inc. (United States)
  • Protagonist Therapeutics, Inc. (United States)
  • Bristol-Myers Squibb (United States)
  • AstraZeneca PLC (United Kingdom)
  • GlaxoSmithKline plc (United Kingdom)
  • Incyte Corporation (United States)
  • AstraZeneca (United Kingdom)
  • Nektar Therapeutics (United States)
  • Next Cure, Inc. (United States)
  • Dicerna Pharmaceuticals, Inc. (United States)
Additional players considered in the study are as follows:
Sanofi (France) , Daiichi Sankyo Co. (Japan) , Novartis AG (Switzerland) , Novo Nordisk A/S (Denmark)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation